Cargando…

Gelsolin as a Potential Clinical Biomarker in Psoriasis Vulgaris

Although discovering novel biomarkers for psoriasis is challenging, it may play an essential role in diagnosis, severity assessment, and prediction of treatment outcome and prognosis. The study was aimed to determine potential serum biomarkers of psoriasis via proteomic data analysis and clinical va...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sul Hee, Park, Young-Lip, Bae, Youin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003618/
https://www.ncbi.nlm.nih.gov/pubmed/36902587
http://dx.doi.org/10.3390/jcm12051801
_version_ 1784904645591695360
author Lee, Sul Hee
Park, Young-Lip
Bae, Youin
author_facet Lee, Sul Hee
Park, Young-Lip
Bae, Youin
author_sort Lee, Sul Hee
collection PubMed
description Although discovering novel biomarkers for psoriasis is challenging, it may play an essential role in diagnosis, severity assessment, and prediction of treatment outcome and prognosis. The study was aimed to determine potential serum biomarkers of psoriasis via proteomic data analysis and clinical validity assessment. Thirty-one subjects manifested psoriasis and 19 subjects were healthy volunteers who were enrolled in the study. Protein expression was performed via two-dimensional gel electrophoresis (2-DE) using psoriasis patients’ sera before and after treatment and sera of patients without psoriasis. Image analysis was then performed. Nano-scale liquid chromatography-tandem mass spectrometry (LC-MS/MS) experiments subsequently identified points showing differential expression in 2-DE image analysis. To measure levels of candidate proteins to validate results obtained from 2-DE, enzyme linked immunosorbent assay (ELISA) was then conducted. Gelsolin was identified as a potential protein through LC-MS/MS analysis and database search. Serum gelsolin levels were lower in the groups of psoriasis patients before treatment than in the control group and the group of psoriasis patients after treatment. Additionally, in subgroup analysis, serum gelsolin level was correlated with various clinical severity scores. In conclusion, low serum gelsolin levels are associated with the severity of psoriasis, proposing the potential role of gelsolin as a biomarker for severity assessment and evaluation of treatment response of psoriasis.
format Online
Article
Text
id pubmed-10003618
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100036182023-03-11 Gelsolin as a Potential Clinical Biomarker in Psoriasis Vulgaris Lee, Sul Hee Park, Young-Lip Bae, Youin J Clin Med Article Although discovering novel biomarkers for psoriasis is challenging, it may play an essential role in diagnosis, severity assessment, and prediction of treatment outcome and prognosis. The study was aimed to determine potential serum biomarkers of psoriasis via proteomic data analysis and clinical validity assessment. Thirty-one subjects manifested psoriasis and 19 subjects were healthy volunteers who were enrolled in the study. Protein expression was performed via two-dimensional gel electrophoresis (2-DE) using psoriasis patients’ sera before and after treatment and sera of patients without psoriasis. Image analysis was then performed. Nano-scale liquid chromatography-tandem mass spectrometry (LC-MS/MS) experiments subsequently identified points showing differential expression in 2-DE image analysis. To measure levels of candidate proteins to validate results obtained from 2-DE, enzyme linked immunosorbent assay (ELISA) was then conducted. Gelsolin was identified as a potential protein through LC-MS/MS analysis and database search. Serum gelsolin levels were lower in the groups of psoriasis patients before treatment than in the control group and the group of psoriasis patients after treatment. Additionally, in subgroup analysis, serum gelsolin level was correlated with various clinical severity scores. In conclusion, low serum gelsolin levels are associated with the severity of psoriasis, proposing the potential role of gelsolin as a biomarker for severity assessment and evaluation of treatment response of psoriasis. MDPI 2023-02-23 /pmc/articles/PMC10003618/ /pubmed/36902587 http://dx.doi.org/10.3390/jcm12051801 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Sul Hee
Park, Young-Lip
Bae, Youin
Gelsolin as a Potential Clinical Biomarker in Psoriasis Vulgaris
title Gelsolin as a Potential Clinical Biomarker in Psoriasis Vulgaris
title_full Gelsolin as a Potential Clinical Biomarker in Psoriasis Vulgaris
title_fullStr Gelsolin as a Potential Clinical Biomarker in Psoriasis Vulgaris
title_full_unstemmed Gelsolin as a Potential Clinical Biomarker in Psoriasis Vulgaris
title_short Gelsolin as a Potential Clinical Biomarker in Psoriasis Vulgaris
title_sort gelsolin as a potential clinical biomarker in psoriasis vulgaris
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003618/
https://www.ncbi.nlm.nih.gov/pubmed/36902587
http://dx.doi.org/10.3390/jcm12051801
work_keys_str_mv AT leesulhee gelsolinasapotentialclinicalbiomarkerinpsoriasisvulgaris
AT parkyounglip gelsolinasapotentialclinicalbiomarkerinpsoriasisvulgaris
AT baeyouin gelsolinasapotentialclinicalbiomarkerinpsoriasisvulgaris